Tumor Reduction with Pazopanib in a Patient with Recurrent Lumbar Chordoma

Imagem de Miniatura
Arquivos
art_RIBEIRO_Tumor_Reduction_with_Pazopanib_in_a_Patient_with_2018.PDF (3.36 MB)
Citações na Scopus
Tipo de produção
article
Data de publicação
2018
DOI
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
HINDAWI LTD
Autores
RIBEIRO, Mauricio Fernando Silva Almeida
SOUSA, Micelange Carvalho de
HANNA, Samir Abdallah
MALDAUN, Marcos Vinicius Calfat
KURIMORI, Ceci Obara
Citação
CASE REPORTS IN ONCOLOGICAL MEDICINE, article ID 4290131, 7p, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Introduction. Chordomas are rare malignancies of bone origin that occur in the axial skeleton, typically the skull base and lumbar/sacral regions. Although often classified as low-grade neoplasms, its locally infiltrative behavior may result in significant morbidity and mortality. Optimal surgical resection may be curative, but up to 50% of the cases relapse within 5 years, and currently there are no systemic treatments approved in this setting. A large proportion of these tumors express stem-cell factor receptor (c-KIT) and platelet-derived growth factor receptors (PDGFRs), providing a rationale for the use of tyrosine-kinase inhibitors (TKIs). Case report. A 27-year-old male presented with recurrent chordoma of the lumbar spine 4 years after initial diagnosis. Salvage therapies in the interval included repeat resections and radiation therapy. He ultimately developed multifocal recurrence not amenable to complete excision or reirradiation. A comprehensive genomic profiling assay was performed and revealed nondrugable alterations. Decision was made to proceed with systemic treatment with pazopanib 800 mg/day, resulting in tumor reduction (-23.1% reduction in size) and prolonged disease control. Conclusion. For this patient with a multiple recurrent chordoma and limited treatment options, pazopanib resulted in sustained clinical benefit following initial tumor reduction.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/27095
Referências
  1. Asklund T., 2012, ACTA ONCOL, V53, P980
  2. Bompas E, 2015, ANN ONCOL, V26, P2168, DOI 10.1093/annonc/mdv300
  3. Casali P. G., 2015, CANCER, V101, P2086
  4. Casali PG, 2014, ANN ONCOL, V25, P113, DOI 10.1093/annonc/mdu256
  5. Di Maio S, 2015, THER CLIN RISK MANAG, V11, DOI 10.2147/TCRM.S50526
  6. George S, 2009, J CLIN ONCOL, V27, P3154, DOI 10.1200/JCO.2008.20.9890
  7. Heery CR, 2015, CANCER IMMUNOL RES, V3, P1248, DOI 10.1158/2326-6066.CIR-15-0119
  8. Heinrich MC, 2008, CLIN CANCER RES, V14, P2717, DOI 10.1158/1078-0432.CCR-07-4575
  9. Lebellec L, 2017, EUR J CANCER, V79, P119, DOI 10.1016/j.ejca.2017.03.037
  10. Lebellec L, 2015, CRIT REV ONCOL HEMAT, V95, P125, DOI 10.1016/j.critrevonc.2015.01.010
  11. Lipplaa A, 2016, CLIN SARCOMA RES, V6, DOI 10.1186/s13569-016-0059-x
  12. Oakley GJ, 2008, MODERN PATHOL, V21, P1461, DOI 10.1038/modpathol.2008.144
  13. Stacchiotti S, 2017, ANN ONCOL, V28, P1230, DOI 10.1093/annonc/mdx054
  14. Stacchiotti S, 2013, ANN ONCOL, V24, P1931, DOI 10.1093/annonc/mdt117
  15. Stacchiotti S, 2009, ANN ONCOL, V20, P1886, DOI 10.1093/annonc/mdp210
  16. Stacchiotti S, 2012, J CLIN ONCOL, V30, P914, DOI 10.1200/JCO.2011.35.3656
  17. Stacchiotti S, 2010, ANN SURG ONCOL, V17, P211, DOI 10.1245/s10434-009-0740-x
  18. Sun X, 2015, CURR REV MUSCULOSKE, V8, P344, DOI 10.1007/s12178-015-9311-x
  19. Tauziede-Espariat A, 2016, J NEUROPATH EXP NEUR, V75, P111, DOI 10.1093/jnen/nlv010
  20. Walcott BP, 2012, LANCET ONCOL, V13, pE69, DOI 10.1016/S1470-2045(11)70337-0
  21. Whelan JS, 2018, J CLIN ONCOL, V36, P188, DOI 10.1200/JCO.2017.75.1743

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICESP